S-2E 是一种具有口服活性且非竞争性的HMG-CoA还原酶和乙酰-CoA 羧化酶 (Acetyl-CoA Carboxylase) 抑制剂。S-2E 具有抗高血脂作用，可用于家族性高胆固醇血症和混合性高脂血症的研究。

S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research [1] [2].

In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at K i =18.11 μM and K i =69.2 μM, respectively [1]. S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats [1].

155730-92-0

C22H25NO4

367.44

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years